登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Lancet，6月24日，Tocilizumab in patients with severe COVID-19: a retrospective cohort study》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-06-26

  • Tocilizumab in patients with severe COVID-19: a retrospective cohort study

    Prof Giovanni Guaraldi, MD †

    Marianna Meschiari, MD †

    Prof Alessandro Cozzi-Lepri, PhD

    Jovana Milic, MD

    Roberto Tonelli, MD

    Marianna Menozzi, MD

    Published:June 24, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30173-9

    Summary

    Background

    No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment.

    Methods

    This retrospective, observational cohort study included adults (≥18 years) with severe COVID-19 pneumonia who were admitted to tertiary care centres in Bologna and Reggio Emilia, Italy, between Feb 21 and March 24, 2020, and a tertiary care centre in Modena, Italy, between Feb 21 and April 30, 2020. All patients were treated with the standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular weight heparin), and a non-randomly selected subset of patients also received tocilizumab. Tocilizumab was given either intravenously at 8 mg/kg bodyweight (up to a maximum of 800 mg) in two infusions, 12 h apart, or subcutaneously at 162 mg administered in two simultaneous doses, one in each thigh (ie, 324 mg in total), when the intravenous formulation was unavailable.

  • 原文来源：https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30173-9/fulltext
186浏览量
原文链接
相关报告

  • 《EClinicalMedicine，6月20日，Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-06-21
    • Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study Author links open overlay panelTariqKewana1FahrettinCovuta1Mohammed J.Al–JaghbeerbLoriRosecK.V.GopalakrishnadBasselAkbikb Show more https://doi.org/10.1016/j.eclinm.2020.100418 Abstract Background Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced cytokine release syndrome and it may provide clinical benefit for selected COVID–19 patients. Methods In this retrospective cohort study, we analyzed hypoxic COVID–19 patients who were consecutively admitted between March 13, 2020 and April 19, 2020. Patients with lung infiltrates and elevated inflammatory markers received a single dose of tocilizumab if no contraindication was present. Systemic steroid, hydroxychloroquine, and azithromycin were concomitantly used for majority of the patients.
    158浏览量
    原文链接

  • 《LANCET，5月29日，Anakinra for severe forms of COVID-19: a cohort study》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-05-30
    • Anakinra for severe forms of COVID-19: a cohort study Thomas Huet, MD Hélène Beaussier, Pharm D Olivier Voisin, MD Stéphane Jouveshomme, MD Gaëlle Dauriat, MD Isabelle Lazareth, MD et al. Show all authors Published:May 29, 2020DOI:https://doi.org/10.1016/S2665-9913(20)30164-8 Summary Background Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been postulated that anakinra, a recombinant IL-1 receptor antagonist, might help to neutralise the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related hyperinflammatory state, which is considered to be one cause of acute respiratory distress among patients with COVID-19. We aimed to assess the off-label use of anakinra in patients who were admitted to hospital for severe forms of COVID-19 with symptoms indicative of worsening respiratory function. Methods The Ana-COVID study included a prospective cohort from Groupe Hospitalier Paris Saint-Joseph (Paris, France) and a historical control cohort retrospectively selected from the Groupe Hospitalier Paris Saint-Joseph COVID cohort, which began on March 18, 2020. Patients were included in the prospective cohort if they were aged 18 years or older and admitted to Groupe Hospitalier Paris Saint-Joseph with severe COVID-19-related bilateral pneumonia on chest x-ray or lung CT scan. The other inclusion criteria were either laboratory-confirmed SARS-CoV-2 or typical lung infiltrates on a lung CT scan, and either an oxygen saturation of 93% or less under oxygen 6 L/min or more, or aggravation (saturation ≤93% under oxygen 3 L/min) with a loss of 3% of oxygen saturation in ambient air over the previous 24 h. The historical control group of patients had the same inclusion criteria. Patients in the anakinra group were treated with subcutaneous anakinra (100 mg twice a day for 72 h, then 100 mg daily for 7 days) as well as the standard treatments at the institution at the time. Patients in the historical group received standard treatments and supportive care. The main outcome was a composite of either admission to the intensive care unit (ICU) for invasive mechanical ventilation or death. The main analysis was done on an intention-to-treat basis (including all patients in the anakinra group who received at least one injection of anakinra).
    39浏览量
    原文链接